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bstract
Chronic paroxysmal hemicrania (CPH) is a rare primary headache syndrome, which is classified along with cluster headache and short-lasting
nilateral neuralgiform headache attacks with conjunctival injection and tearing as a trigeminal autonomic cephalalgia (TACs). Hemicrania
ontinua (HC) was previously classified as one of the TACs, but in the recent second classification of the International Headache Society this
isorder was moved to the group of other primary headaches.
Both CPH and HC are characterised by moderate to excruciating pain requiring pharmacological treatment; furthermore, both conditions
re characterised by an absolute response to indomethacin, which represents one of the current diagnostic criteria for these two syndromes.
nfortunately, in about one-fourth of cases treatment with indomethacin may cause adverse events, mostly gastrointestinal. We report one
ubject with CPH and another with HC intolerant to indomethacin, who responded remarkably well to topiramate.
2007 Elsevier B.V. All rights reserved.
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Trigeminal autonomic cephalgias (TACs) are a group of
rimary headaches characterised by unilateral pain in the
omatic distribution of the trigeminal nerve with ipsilat-
ral autonomic features [1,2]. TACs, which include cluster
eadache, paroxysmal hemicrania (PH) and short-lasting
nilateral neuralgiform headache attacks with conjunctival
njection and tearing (SUNCT), have been grouped into Sec-
ion 3 by the recent International Classification of Headache
isorders, 2nd edition (ICHD-II) [3]. Hemicrania continuaHC) was previously included in the umbrella term of TACs
4], but was then moved into Section 4 of the ICHD-II criteria,
ncluding other primary headaches [3].
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oi:10.1016/j.clineuro.2007.09.002PH and HC have common elements, such as the presence
f autonomic features and moderate to excruciating pain in
he temporal-orbital region. Furthermore, both conditions are
haracterised by an absolute response to indomethacin, which
epresents one of the current diagnostic criteria for these two
yndromes [3]. While PH is characterised by short-lasting
evere attacks, HC is, however, a continous headache and it
hould be considered in the differential diagnosis of chronic
aily headache [5].
Due to the high disability associated with PH and HC,
hese headache disorders require specific acute and preven-
ive treatments. However, treatment with indomethacin for
hese conditions is limited by the potential for systemic toxi-
ity, mostly gastrointestinal [6]. For these reasons alternative
rugs, with a better-tolerated profile, have been proposed for
he treatment of PH and HC [1,2,7–9]. In particular, three
ase reports have recently suggested the potential use of top-
ramate as a preventive treatment for chronic PH (CPH) [7]
nd HC [8,9].
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In this paper we report two patients: one with CPH and
nother with HC, who were effectively treated with topira-
ate due to intolerance to indomethacin.
. Case report
.1. Patient 1
A 44-year-old woman was referred to our Headache Cen-
re for stabbing headache attacks, which had started 2 years
arlier. She described excruciating, left-sided temporal and
rbital headache attacks, which usually lasted for 15–20 min
ith a frequency of up to 20 episodes per day. On two occa-
ions the attacks lasted for up to 1 h. The pain occurred
egularly throughout the day and it was associated with ipsi-
ateral lacrimation, nasal congestion and rhinorrhoea. During
hese attacks, the patient preferred to sit or lie still. The attacks
ere not triggered by neck movements or alcohol consump-
ion, physical activity, lack of sleep or eating. The patient
elated that from the onset of her symptoms, she experienced
bout five pain attacks per day, but the frequency progres-
ively increased every few months and, in the 1-year period
rior to admission, they occurred almost daily with remission
eriods of less than 10 days.
Before coming to our centre the patient was diagnosed
ith cluster headache and treated with prednisone 50 mg a
ay and verapamil 240 mg a day with a slight effect. She had
ried subcutaneous sumatriptan 6 mg once with moderate pain
elief but this was immediately discontinued due to severe
ausea and vomiting. Treatment with oxygen (100%, 7 l/min
or 15 min) moderately relieved the attacks.
Physical and neurological examinations on admission
ere normal. Routine blood tests, ECG and a brain MRI
ith gadolinium were unremarkable. Past medical history
as negative; a family history showed that her mother suf-
ered from migraine. She was started on indomethacin with
low titration to 50 mg three times per day with maximum
ffectiveness 2 days after initiating the effective dose; a gas-
roprotective therapy with omeprazole 20 mg a day was also
rescribed. The clinical picture and response to indomethacin
onfirmed a diagnosis of CPH, based on ICHD-II crite-
ia [3]. After 2 months she developed dyspepsia and we
ttempted to slowly withdraw indomethacin with pain reap-
earance within a few days. After a further 1-month period,
ndomethacin was withdrawn because of the increasing epi-
astric pain that on some occasions was associated with
evere vomiting. Thus, she was started on topiramate with
low titration to 100 mg twice a day, with complete pain relief
fter few days of initiating the effective dose. After 3 months,
he developed moderate leg paraesthesia and we attempted
o slowly withdraw topiramate with pain recurrence at the
ose of 50 mg twice a day. Thereafter, an intermediate dose of
5 mg twice a day daily was reached with a substantial reduc-
ion of the sensory symptoms and complete pain relief. Three
onths later, we gradually discontinued topiramate, reducing
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t by 25 mg a week. After a further 6 months the patient no
onger experienced attacks and there were no adverse effects
rom topiramate.
.2. Patient 2
A 39-year-old man was referred to our Headache Centre,
aving experienced daily persistent headaches for 6 months.
e had a 4-year history of remitting headache lasting weeks to
onths, with long-lasting remissions. There were no precip-
tating factors. He described a strictly unilateral, right-sided,
on-pulsatile, pressing headache, which started in the frontal
egion and the orbit with radiation to the parietal region. The
eadache was usually of moderate intensity with exacerba-
ions of severe pain. The attacks had a throbbing quality and
ere associated with ipsilateral lacrimation and conjunctival
njection but not with other autonomic features or migraine
ccompanying symptoms, such as nausea, vomiting, photo-
r phonophobia. The headache was not triggered by neck
ovements or exacerbated by alcohol consumption, physi-
al activity, lack of sleep or eating. Past medical history was
egative with the exception of Helicobacter pylori-negative
astric ulcers, diagnosed on gastroscopy, treated with gastro-
rotective agents and attributed to NSAID 3 years prior to
dmission. There was no family history of headache, he was
non-smoker and drank no more than one glass of red wine
day.
The patient was taking ibuprofen 600 mg tablets twice
day for moderate pain with a partial response but other
SAID were totally ineffective during exacerbations of
evere pain, which required intramuscular ketorolac 30 mg
wice a day with some relief. He had previously tried other
SAID (i.e., aspirin, naproxen, piroxicam, rofecoxib), corti-
osteroids, benzodiazepines, and tricyclic antidepressants to
o effect.
Physical and neurological examinations on admission
ere normal. Routine blood tests, ECG and a brain MRI
ith gadolinium were unremarkable. He was started on
ndomethacin 25 mg three times per day with a total headache
elief within 24 h. We also prescribed a gastroprotective ther-
py with omeprazole 20 mg a day. The clinical presentation
nd response to indomethacin confirmed a diagnosis of HC
ased on ICHD-II criteria [3]. The patient was pain-free for
weeks and after this period he developed severe epigas-
ric pain, thereby necessitating cessation of indomethacin,
hich led to the recurrence of the headache within 3 days.
hereafter, he was started on topiramate with slow titration
o 50 mg twice a day, with complete pain remission after 2
eeks. After 6 months we attempted to slowly withdraw topi-
amate. One day after the patient had reached a dose of 25 mg
wice a day, pain recurred and topiramate was gradually
itrated to the previous dose, which rendered him completely
ain-free in about 15 days. At 1-year follow-up, he still has
ood control of his episodes. When he reduces the dose,
he episodes return. He has reported no side-effects from
opiramate.
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. Discussion
We have reported two patients who fulfil the ICHD-II crite-
ia [3] for CPH and HC, intolerant to indomethacin, who fully
esponded to topiramate. The dose of topiramate required
or complete pain relief was somewhat less than that usually
eeded for the antiepileptic effect of the drug for all patients
10], but similar to that previously described for the treatment
f CPH and HC [7–9]. Of interest, both patients responded
o treatment with topiramate incurring relatively few side
ffects. Furthermore, patient 1 – suffering from CPH – expe-
ienced persistent pain relief after topiramate withdrawal.
CPH and HC cause patients considerable disability and
he severe nature of the pain requires the use of effective
ombinations of acute and preventive treatment from the out-
et. Indomethacin, the specific preventive treatment for both
H and HC [3], in about 25% of treated patients may cause
dverse gastrointestinal effects [6], similar to those which
ppeared in our cases.
For these reasons alternative therapies, with favorable
harmacokinetic properties and side effects – such as the
ewer antiepileptic drugs – have been proposed for the pre-
entive treatment of CPH and HC [1,2,7–9]. In particular, one
ase with CPH [7] and four cases with HC [8,9], responding
o topiramate, have been described. Our results confirm and
xtend previous reports, thereby suggesting the potential use
f topiramate in CPH and HC in those patients who are intol-
rant to indomethacin. Indeed, the drug has also been proved
o be effective as a preventive treatment of migraine [11].
urthermore, it has been used to treat chronic tension-type
eadache [12] and hypnic headache [13]. Lastly, topiramate
as been reported to be beneficial in cluster headache [14]
nd SUNCT [15], both disorders included in the umbrella
erm of TACs.
t
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able 1
ummary of subjects with chronic paroxysmal hemicrania and hemicrania continua
uthors Age (years),
sex
Mean effective
dose (mg/day)
Overall response
aroxysmal hemicrania
Cohen et al. [7] 42, man 200–350 100% remission
Patient 1 of this study 44, woman 200 100% remission
emicrania continua
Matharu et al. [8] 40, woman 100 100% remission
64, man 200 100% remission
Brighina et al. [9] 30, woman 200 100% remission
46, woman 200 100% remission
Patient 2 of this study 39, man 100 100% remission
Es: adverse effects.d Neurosurgery 110 (2008) 88–91
Summarizing our cases and previous case reports [7–9]
pecifically focused on the preventive treatment with topira-
ate of CPH and HC, some suggestions can be made (see
able 1): (a) the mean effective topiramate dose for CPH is at
east 200 mg/day. However, with this or higher doses there is a
ossibility of adverse effects, thus reaching a dose of approx-
mately 150 mg/day could safely control both adverse effects
nd headache attacks; (b) the mean effective topiramate dose
or HC ranges from 100 to 200 mg/day. This dose appears to
e well-tolerated in young adults, while using a 200 mg/day
ose in adult-to-elderly subjects may cause severe adverse
ffects, leading to topiramate withdrawal.
Considering the high placebo response reported in clinical
rials on preventive medications in TACs [16], these con-
iderations should be interpreted with caution. However, the
ersistence of the therapeutic effect of topiramate after the
uspension of treatment, as shown by the patient with CPH in
he present study and described in the two HC cases reported
y Brighina et al. [9], it can hardly be attributed to a purely
lacebo effect.
Topiramate is a derivative of the monosaccaridhe d-
ructose that has demonstrated antiepileptic activity [10].
ts multiple action mechanisms include: voltage-sensitive,
odium channel blockade; calcium channel inhibition;
ncrease of potassium conductance; -aminobutyric-acid-
ediated chloride current increment; glutamate-mediated
eurotransmission inhibition; and carbonic anhydrase isoen-
yme inhibition [10]. It is not known on which of these
echanism(s) topiramate acts as a prophylactic treatment
or various headache syndromes. The direct inhibition of the
rigeminocervical complex or the modulation of neurons that
egulate sensory input have been proposed to be plausible
echanisms for the topiramate action as a preventive treat-
ent for TACs and migraine [17,18]. Of interest Goadsby et
who have been treated with topiramate
AEs Recurrence on
withdrawal
Withdrawal because of
AEs
Cognitive slowing, dry
mouth and weight loss
Yes No (reduction to
150 mg/day with
substantial pain
control)
Mild paraesthesias Yes No (reduction to
150 mg/day with
substantial pain
control)
No Yes NA
Cognitive slowing,
behavioural problems
and paraesthesias
Yes Yes
No No NA
No Yes NA
No Yes NA
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[20] Malick A, Burstein R. Cells of origin of the trigeminohypothalamicC. Camarda et al. / Clinical Neuro
l. [19] have previously suggested that the pathophysiology
f TACs and HC revolves around the trigeminal-autonomic
eflex. In particular, the cranial autonomic symptoms promi-
ent in TACs and HC may be due to a central disinhibition
f the trigeminal-autonomic reflex by the hypothalamus,
ossibly through direct hypothalamic-trigeminal connections
20]. This hypothesis is further strengthened by recent find-
ngs of a posterior hypotalamic activation both in TACs
nd HC [21].
According to our observations, topiramate would be an
nteresting alternative option in patients with CPH and HC
ith contraindications or intolerance to indomethacin. Our
bservations need to be confirmed by controlled clinical tri-
ls.
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